Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Dec;62(6):959–965. doi: 10.1038/bjc.1990.417

Reduced nuclear binding of a DNA minor groove ligand (Hoechst 33342) and its impact on cytotoxicity in drug resistant murine cell lines.

S A Morgan 1, J V Watson 1, P R Twentyman 1, P J Smith 1
PMCID: PMC1971566  PMID: 2257227

Abstract

The reduced cellular uptake, and subsequent reduced nuclear availability, of cytotoxic agents is a factor in the resistance of mammalian cells to anti-cancer drugs that act by interaction with DNA. The whole cell uptake, nuclear binding and cytotoxicity of a DNA-specific ligand, Hoechst dye number 33342 (Ho342), has been studied in cytotoxic drug resistant variants of a murine tumour cell line. Cell lines showing various degrees of cross-resistance to adriamycin as a part of the phenotype of classical multi-drug resistance (MDR) demonstrated a reduction in intranuclear Ho342 content, up to a maximum of 35% of the level found in the parent as assessed by flow cytometry, despite similar levels of whole cell uptake determined using radiolabelled ligand. Ability to limit nuclear accessibility of Ho342 correlated closely with cellular resistance to Ho342 and to adriamycin. All drug resistant cell lines showed a significant increase in nuclear accessibility to Ho342 after verapamil treatment, including a methotrexate resistant cell line. The methotrexate resistant variant, not demonstrating MDR, showed reduced nuclear binding of Ho342 but increased cell kill associated with a propensity to develop a population of cells showing extra DNA replication in response to Ho342 exposure. Differences between cell lines in the relationship between Ho342-induced cell cycle perturbation and cell kill supported the conclusion that modulation of several pathways of response to cytotoxic agents had occurred in the development of drug resistance.

Full text

PDF
959

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlogie B., Drewinko B., Johnston D. A., Freireich E. J. The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Res. 1976 Jun;36(6):1975–1979. [PubMed] [Google Scholar]
  2. Coley H. M., Twentyman P. R., Workman P. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol. 1989;24(5):284–290. doi: 10.1007/BF00304759. [DOI] [PubMed] [Google Scholar]
  3. Coley H. M., Twentyman P. R., Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol. 1989 Dec 15;38(24):4467–4475. doi: 10.1016/0006-2952(89)90658-8. [DOI] [PubMed] [Google Scholar]
  4. Durand R. E., Olive P. L. Cytotoxicity, Mutagenicity and DNA damage by Hoechst 33342. J Histochem Cytochem. 1982 Feb;30(2):111–116. doi: 10.1177/30.2.7061816. [DOI] [PubMed] [Google Scholar]
  5. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  6. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gerlach J. H., Endicott J. A., Juranka P. F., Henderson G., Sarangi F., Deuchars K. L., Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature. 1986 Dec 4;324(6096):485–489. doi: 10.1038/324485a0. [DOI] [PubMed] [Google Scholar]
  8. Glisson B. S., Ross W. E. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther. 1987;32(2):89–106. doi: 10.1016/0163-7258(87)90054-4. [DOI] [PubMed] [Google Scholar]
  9. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  10. Krishan A. Effect of drug efflux blockers on vital staining of cellular DNA with Hoechst 33342. Cytometry. 1987 Nov;8(6):642–645. doi: 10.1002/cyto.990080618. [DOI] [PubMed] [Google Scholar]
  11. Lalande M. E., Ling V., Miller R. G. Hoechst 33342 dye uptake as a probe of membrane permeability changes in mammalian cells. Proc Natl Acad Sci U S A. 1981 Jan;78(1):363–367. doi: 10.1073/pnas.78.1.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Latt S. A., Stetten G. Spectral studies on 33258 Hoechst and related bisbenzimidazole dyes useful for fluorescent detection of deoxyribonucleic acid synthesis. J Histochem Cytochem. 1976 Jan;24(1):24–33. doi: 10.1177/24.1.943439. [DOI] [PubMed] [Google Scholar]
  13. Morgan S. A., Watson J. V., Twentyman P. R., Smith P. J. Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer. Br J Cancer. 1989 Sep;60(3):282–287. doi: 10.1038/bjc.1989.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Reeve J. G., Wright K. A., Rabbitts P. H., Twentyman P. R., Koch G. Collateral resistance to verapamil in multidrug-resistant mouse tumor cells. J Natl Cancer Inst. 1989 Oct 18;81(20):1588–1590. doi: 10.1093/jnci/81.20.1588. [DOI] [PubMed] [Google Scholar]
  15. Schimke R. T. Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer. 1986 May 15;57(10):1912–1917. doi: 10.1002/1097-0142(19860515)57:10<1912::aid-cncr2820571004>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  16. Smith P. J., Lacy M., Debenham P. G., Watson J. V. A mammalian cell mutant with enhanced capacity to dissociate a bis-benzimidazole dye-DNA complex. Carcinogenesis. 1988 Mar;9(3):485–490. doi: 10.1093/carcin/9.3.485. [DOI] [PubMed] [Google Scholar]
  17. Smith P. J., Nakeff A., Watson J. V. Flow-cytometric detection of changes in the fluorescence emission spectrum of a vital DNA-specific dye in human tumour cells. Exp Cell Res. 1985 Jul;159(1):37–46. doi: 10.1016/s0014-4827(85)80035-5. [DOI] [PubMed] [Google Scholar]
  18. Smith P. J. Relationship between a chromatin anomaly in ataxia-telangiectasia cells and enhanced sensitivity to DNA damage. Carcinogenesis. 1984 Oct;5(10):1345–1350. doi: 10.1093/carcin/5.10.1345. [DOI] [PubMed] [Google Scholar]
  19. Taylor I. W., Milthorpe B. K. An evaluation of DNA fluorochromes, staining techniques, and analysis for flow cytometry. I. Unperturbed cell populations. J Histochem Cytochem. 1980 Nov;28(11):1224–1232. doi: 10.1177/28.11.6159392. [DOI] [PubMed] [Google Scholar]
  20. Triton T. R., Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science. 1982 Jul 16;217(4556):248–250. doi: 10.1126/science.7089561. [DOI] [PubMed] [Google Scholar]
  21. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982 Nov;42(11):4730–4733. [PubMed] [Google Scholar]
  22. Twentyman P. R., Fox N. E., Wright K. A., Bleehen N. M. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer. 1986 Apr;53(4):529–537. doi: 10.1038/bjc.1986.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Twentyman P. R., Fox N. E., Wright K. A., Workman P., Broadhurst M. J., Martin J. A., Bleehen N. M. The in vitro effects and cross-resistance patterns of some novel anthracyclines. Br J Cancer. 1986 May;53(5):585–594. doi: 10.1038/bjc.1986.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Twentyman P. R., Reeve J. G., Koch G., Wright K. A. Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin). Br J Cancer. 1990 Jul;62(1):89–95. doi: 10.1038/bjc.1990.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Watson J. V., Chambers S. H., Smith P. J. A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry. 1987 Jan;8(1):1–8. doi: 10.1002/cyto.990080101. [DOI] [PubMed] [Google Scholar]
  26. Watson J. V., Sikora K., Evan G. I. A simultaneous flow cytometric assay for c-myc oncoprotein and DNA in nuclei from paraffin embedded material. J Immunol Methods. 1985 Oct 24;83(1):179–192. doi: 10.1016/0022-1759(85)90071-7. [DOI] [PubMed] [Google Scholar]
  27. Zimmer C., Wähnert U. Nonintercalating DNA-binding ligands: specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. Prog Biophys Mol Biol. 1986;47(1):31–112. doi: 10.1016/0079-6107(86)90005-2. [DOI] [PubMed] [Google Scholar]
  28. Zwelling L. A., Michaels S., Erickson L. C., Ungerleider R. S., Nichols M., Kohn K. W. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry. 1981 Nov 10;20(23):6553–6563. doi: 10.1021/bi00526a006. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES